MiNK Therapeutics, Inc. (NASDAQ:INKT) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) have been given a consensus rating of “Moderate Buy” by the five ratings firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $37.50.

A number of equities research analysts recently issued reports on the stock. B. Riley raised shares of MiNK Therapeutics to a “strong-buy” rating in a research note on Friday, July 18th. William Blair downgraded shares of MiNK Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Friday, July 11th. HC Wainwright raised shares of MiNK Therapeutics from a “neutral” rating to a “buy” rating and set a $35.00 price target on the stock in a research note on Friday, August 15th. Wall Street Zen downgraded shares of MiNK Therapeutics to a “strong sell” rating in a research note on Saturday. Finally, Zacks Research downgraded shares of MiNK Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, August 18th.

MiNK Therapeutics Stock Performance

INKT stock opened at $14.90 on Friday. MiNK Therapeutics has a one year low of $4.56 and a one year high of $76.00. The company’s fifty day moving average price is $14.65 and its 200-day moving average price is $10.42. The company has a market capitalization of $67.35 million, a PE ratio of -5.17 and a beta of 0.33.

MiNK Therapeutics (NASDAQ:INKT) last released its earnings results on Thursday, August 14th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.51). On average, research analysts predict that MiNK Therapeutics will post -2.75 EPS for the current fiscal year.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.